WebJul 5, 2024 · THOR-707 Q3W at recommended Phase 2 dose (RP2D) with a checkpoint inhibitor via IV administration Q6W will consist of one 9-week cycle of THOR monotherapy … WebApr 9, 2024 · 这一PEG修饰不但提高IL-2蛋白的稳定性 ,而且让它无法与IL-2受体α结合。这一设计让THOR-707在刺激CD8阳性T细胞和天然杀伤细胞的同时 ,不会同时激发具有免疫抑制功能的Treg的活性。 THOR-707示意图(图片来源:Synthorx公司官网)
A Study Evaluating Safety and Therapeutic Activity of THOR-707 in …
WebTHOR-707 is a reprogrammed, site-directed, single pegylated, recombinant human IL-2 (rIL-2) variant that lacks binding affinity for the α chain of the IL-2 receptor. Because THOR … WebJun 27, 2024 · THOR-707 Q3W at recommended Phase 2 dose (RP2D) with a checkpoint inhibitor via IV administration Q6W will consist of one 9-week cycle of THOR monotherapy on Cycle 1 Day 1 followed by THOR-707 Q3W + checkpoint inhibitor at Cycle 1 Day 22. Subsequently treatment will consist of repeated 6-weeks cycles with combination therapy. thieves neck woodford
481 Phase 1/2 study of THOR-707 (SAR444245), a pegylated recombinant …
WebOct 28, 2024 · Sanofi has been working on this IL-2 candidate since 2024 when it acquired San Diego-based Synthorx for a value of $2.5 billion. The deal gave Sanofi control over … WebApr 10, 2024 · THOR-707-101 An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and in a Combination Therapy in Adult Subjects with Advanced or Metastatic Solid Tumors Dr Tira Tan NCT04009681: Open: 12 All Solid Tumour Advanced recurrent TAPISTRY WebJun 4, 2024 · A Phase 1/2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR- 707) Combined With Cemiplimab for … thieves night on the town